Clinical TrialsSearch results
Number of results: 817
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- Shikamura Mitsuhiro
- 2024-03-15
Recruiting
- A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
- Ovarian Cancer, Solid Tumors
- Fukunaga Shinichi
- 2024-04-27
Recruiting
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Hematological Malignancies
- Fujikawa Ei
- 2022-02-19
Recruiting
- A Study on Optimizing Setup Margins in Carbon Ion Radiotherapy
- Lung cancer, prostate cancer, liver cancer, breast cancer, kidney cancer
- Okonogi Noriyuki
- 2023-06-08
Recruiting
- A study on pharmacist interventions to improve eye drop adherence in glaucoma patients.
- glaucoma
- Yuko Sekine
- 2024-03-27
Recruiting
- A study on single antiplatelet therapy after WATCHMAN FLX pro device closure in non-valvular atrial fibrillation
- non-valvular atrial fibrillation
- Kondo Yusuke
- 2024-06-19
Recruiting
- A Study to Evaluate the Efficacy and Safety of VR-205 in Primary IgA Nephropathy Patients at Risk of Developing End-Stage Renal Disease (ESRD)
- Primary IgA Nephropathy
- Itoigawa Suguru
- 2024-04-24
Recruiting
- A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.
- ER+/HER2 Advanced Breast Cancer
- Kawai Norisuke
- 2023-02-22
Recruiting
- A study to test different doses of BI 765049 alone and in combination with ezabenlimab in Asian people with advanced cancer (solid tumours) positive for B7-H6
- B7-H6-positive GC, CRC, PDAC, HCC, HNSCC, or NSCLC patients
- Hagimori Kenta
- 2024-01-26
Recruiting
- Addition of binimetinib after refractory to encorafenib and cetuximab in patients with BRAF V600E-mutant metasta
tic colorectal cancer
- Unresectable, advanced or recurrent colorectal cancer with BRAF V600E mutation
- Bando Hideaki
- 2022-01-01